Lazaridis, Lazaros
Schmidt, Teresa
Oster, Christoph
Blau, Tobias
Pierscianek, Daniela
Siveke, Jens T.
Bauer, Sebastian
Schildhaus, Hans-Ulrich
Sure, Ulrich
Keyvani, Kathy
Kleinschnitz, Christoph
Stuschke, Martin
Herrmann, Ken
Deuschl, Cornelius
Scheffler, Björn
Kebir, Sied
Glas, Martin
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 5 April 2022
Accepted: 29 April 2022
First Online: 12 August 2022
Declarations
:
: Lazaros Lazaridis received honoraria and travel support from Novocure. Teresa Schmidt received honoraria and travel support from Novocure. Jens T. Siveke reports research funding from BMS, Celgene and Roche; consulting and personal fees from AstraZeneca, Bayer, Baxalta, BMS, Celgene, Immunocore, Lilly, Novartis, Roche, Shire; has minor equity in FAPI Holding and Pharma15 (< 3%) and is a member of the Board of Directors for Pharma15 outside the submitted work. Jens T. Siveke is supported by the German Cancer Consortium (DKTK). Sebastian Bauer reports personal fees from Deciphera, grants from Incyte, grants and personal fees from Blueprint Medicines, personal fees from Lilly, grants and personal fees from Novartis, personal fees from Daichii-Sankyo, personal fees from Plexxikon, personal fees from Exelixis, personal fees from Bayer, and others from Pfizer, during the conduct of the study; personal fees from Pharmamar, personal fees from Lilly, personal fees from Roche, and personal fees from GSK, outside the submitted work. Björn Scheffler is supported by the German Cancer Consortium (DKTK) and the DFG-CRU337. Sied Kebir received honoraria and travel support from Novocure. Martin Glas reports honoraria from Roche, Novartis, UCB, Abbvie, Daiichi Sankyo, Novocure, Bayer, Janssen-Cilag, Medac, Merck, Kyowa Kirin; travel support from Novocure and Medac; research grant from Novocure. All remaining authors have declared no conflicts of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University Duisburg-Essen (August 12, 2020; application number: 20–9431-BO).
: For this type of study (retrospective and anonymous analysis) formal consent is not required.